Guidance in Social and Ethical Issues Related to Clinical, Diagnostic Care and Novel Therapies for Hereditary Neuromuscular Rare Diseases: “Translating“ the Translational

Drug trials in children engage with many ethical issues, from drug-related safety concerns to communication with patients and parents, and recruitment and informed consent procedures. This paper addresses the field of neuromuscular disorders where the possibility of genetic, mutation-specific treatments, has added new complexity. Not only must trial design address issues of equity of access, but researchers must also think through the implications of adopting a personalised medicine approach, which requires a precise molecular diagnosis, in addition to other implications of developing orphan drugs. It is against this background of change and complexity that the Project Ethics Council (PEC) was established within the TREAT-NMD EU Network of Excellence. The PEC is a high level advisory group that draws upon the expertise of its interdisciplinary membership which includes clinicians, lawyers, scientists, parents, representatives of patient organisations, social scientists and ethicists. In this paper we describe the establishment and terms of reference of the PEC, give an indication of the range and depth of its work and provide some analysis of the kinds of complex questions encountered. The paper describes how the PEC has responded to substantive ethical issues raised within the TREAT-NMD consortium and how it has provided a wider resource for any concerned parent, patient, or clinician to ask a question of ethical concern. Issues raised range from science related ethical issues, issues related to hereditary neuromuscular diseases and the new therapeutic approaches and questions concerning patients rights in the context of patient registries and bio-banks. We conclude by recommending the PEC as a model for similar research contexts in rare diseases.

[1]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[2]  A. Ferlini.  Neuromuscular disease: Muscular dystrophy—something new on God's green earth? , 2012, Nature Reviews Neurology.

[3]  K. Bushby,et al.  Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. , 2011, Clinical investigation.

[4]  Johan T den Dunnen,et al.  Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.

[5]  Delayed publication of clinical trials in cystic fibrosis☆ , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[6]  Benjamin Kyneswood.  The ethics of research with children and young people: a practical handbook , 2011 .

[7]  G. Piluso,et al.  Limb girdle muscular dystrophies: update on genetic diagnosis and therapeutic approaches. , 2011, Current opinion in neurology.

[8]  F. Muntoni,et al.  Genetic treatments in muscular dystrophies , 2007, Current opinion in neurology.

[9]  R. Horton.  Trial registers: protecting patients, advancing trust , 2006, The Lancet.

[10]  J. Grieger,et al.  Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  A. Smyth,et al.  Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study , 2012, BMJ : British Medical Journal.

[12]  Yaffa R Rubinstein,et al.  Informed consent process for patient participation in rare disease registries linked to biorepositories. , 2012, Contemporary clinical trials.

[13]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[14]  J. Fegert,et al.  Ethics in child and adolescent psychiatric care: An international perspective , 2010, International review of psychiatry.

[15]  L. Naldini.  Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.

[16]  B. Engelen,et al.  The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and Polyneuropathies): Development and preliminary data , 2007, Neuromuscular Disorders.

[17]  E. Cave.  Seen but not heard? Children in clinical trials. , 2014, Medical law review.

[18]  S. Woods,et al.  Disputing the Ethics of Research: The Challenge from Bioethics and Patient Activism to the Interpretation of the Declaration of Helsinki in Clinical Trials , 2013, Bioethics.

[19]  L. Ross.  Screening for conditions that do not meet the Wilson and Jungner criteria: The case of Duchenne muscular dystrophy , 2006, American journal of medical genetics. Part A.

[20]  M. Emborg,et al.  Beyond Access vs. Protection in Trials of Innovative Therapies , 2010, Science.

[21]  A. M. Moliner.  Creating a European Union framework for actions in the field of rare diseases. , 2010, Advances in experimental medicine and biology.

[22]  W. Ludwig,et al.  The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication. , 2010, Deutsches Arzteblatt international.

[23]  F. Muntoni,et al.  Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges. , 2012, Current gene therapy.

[24]  K. Bushby,et al.  Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. , 2009, Brain : a journal of neurology.

[25]  S. Athar.  Principles of Biomedical Ethics , 2011, The Journal of IMA.

[26]  Harlan M Krumholz,et al.  Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis , 2012, BMJ : British Medical Journal.

[27]  D. Radice,et al.  Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial , 2011, The Lancet Neurology.

[28]  J. E. Wraith,et al.  Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience , 2010, Journal of Inherited Metabolic Disease.

[29]  P. Alderson,et al.  The Ethics of Research with Children and Young People: A Practical Handbook , 2011 .

[30]  G. V. Ommen,et al.  The risks of therapeutic misconception and individual patient (n =1) “trials” in rare diseases such as Duchenne dystrophy , 2011, Neuromuscular Disorders.

[31]  J. Boos,et al.  Randomized clinical trials in children--ethical and methodological issues. , 2010, Current pharmaceutical design.

[32]  A. Ferlini,et al.  Best Practice Guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies , 2010, Neuromuscular Disorders.

[33]  A. Ferlini,et al.  Early corticosteroid treatment in 4 duchenne muscular dystrophy patients: 14‐year follow‐up , 2012, Muscle & nerve.

[34]  I. Graham,et al.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.

[35]  S. Woods,et al.  Therapeutic Misconception: Hope, Trust and Misconception in Paediatric Research , 2014, Health Care Analysis.

[36]  A. Davidson,et al.  Ethics and medical research in children , 2009, Paediatric anaesthesia.

[37]  P. Gøtzsche,et al.  Access to data in industry-sponsored trials , 2011, The Lancet.

[38]  M. Pane,et al.  Muscle magnetic resonance imaging in congenital myopathies due to ryanodine receptor type 1 gene mutations. , 2011, Archives of neurology.

[39]  B. Byrne,et al.  Sustained alpha‐sarcoglycan gene expression after gene transfer in limb‐girdle muscular dystrophy, type 2D , 2010, Annals of neurology.

[40]  L. Hagger.  The Child As Vulnerable Patient: Protection and Empowerment , 2009 .

[41]  Z. Bankowski,et al.  Council for International Organizations of Medical Sciences , 1991 .

[42]  David Coultas,et al.  Ethical considerations in the interpretation and communication of clinical trial results. , 2007, Proceedings of the American Thoracic Society.